During the past decade, Institute for Cardiovascular Diseases of Vojvodina conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 5 clinical trials were completed, i.e. on average, 38.5% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 2 clinical trials were completed. i.e. 40% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institute for Cardiovascular Diseases of Vojvodina" #1 sponsor was "Arena Pharmaceuticals" with 1 trials, followed by "AstraZeneca" with 1 trials sponsored, "Boehringer Ingelheim" with 1 trials sponsored, "Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company" with 1 trials sponsored and "Daiichi Sankyo, Inc." with 1 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institute for Cardiovascular Diseases of Vojvodina" #1 collaborator was "Azienda Ospedaliero-Universitaria Careggi" with 1 trials as a collaborator, "Charite University, Berlin, Germany" with 1 trials as a collaborator, "Clinres Farmacija d.o.o." with 1 trials as a collaborator, "Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)" with 1 trials as a collaborator and "Eli Lilly and Company" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Institute for Cardiovascular Diseases of Vojvodina" are "Coronary Artery Disease" (3 trials), "Acute Myocardial Infarction" (2 trials), "Atrial Fibrillation" (2 trials), "ACS (Acute Coronary Syndrome)" (1 trials) and "Acute Heart Failure With Reduced Ejection Fraction" (1 trials). Many other conditions were trialed in "Institute for Cardiovascular Diseases of Vojvodina" in a lesser frequency.

Most popular intervention types in "Institute for Cardiovascular Diseases of Vojvodina" are "Drug" (13 trials), "Behavioral" (1 trials), "Combination Product" (1 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Edoxaban" (2 trials), "APD418" (1 trials), "Add-on therapy" (1 trials) and "Amlessa®" (1 trials). Other intervention names were less common.

The vast majority of trials in "Institute for Cardiovascular Diseases of Vojvodina" are 17 trials for "All" genders.

Currently, there are NaN active trials in "Institute for Cardiovascular Diseases of Vojvodina". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 11 completed trials in Institute for Cardiovascular Diseases of Vojvodina, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Institute for Cardiovascular Diseases of Vojvodina, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 2 trials that are defined as “Not Applicable".